Elevated intraocular pressure: Treatment of elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma for whom monotherapy provides an insufficient reduction in IOP

Brinzolamide inhibits carbonic anhydrase, leading to decreased aqueous humor secretion. This results in a reduction of intraocular pressure.
Timolol: Blocks both beta1- and beta2-adrenergic receptors, reduces intraocular pressure by reducing aqueous humor production or possibly outflow.

See individual agents.

Hypersensitivity to brinzolamide, timolol, other beta-blockers, sulfonamides, or any component of the formulation; current or history of bronchial asthma; severe chronic obstructive pulmonary disease (COPD); severe allergic rhinitis and bronchial hyper-reactivity; sinus bradycardia, sick sinus syndrome, sino-atrial block, second-/third degree atrioventricular (AV) block, overt cardiac failure, cardiogenic shock; hyperchloremic acidosis; severe renal impairment (CrCl <30 mL/minute)

C

Timolol is excreted in breast milk following oral and ophthalmic administration, though clinical beta blockade is not likely at recommended ophthalmologic doses. It is unknown whether brinzolamide is excreted in breast milk. Use of the combination product during lactation is not recommended. See individual agents.

1% to 10%:
Central nervous system: Foreign body sensation of eye (1%)
Gastrointestinal: Dysgeusia (2%)
Ophthalmic: Blurred vision (6%), eye irritation (4%), eye pain (3%)

Elevation of intraocular pressure: Ophthalmic: Instill 1 drop in affected eye(s) twice daily.